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ABSTRACT 
OBJECTIVE The mechanism causing gastrointestinal intolerance to metformin treatment is 
unknown. We have previously shown that reduced-function alleles of organic cation 
transporter 1 (OCT1) are associated with increased intolerance to metformin. Considering 
recent findings that serotonin transporter (SERT) might also be involved in metformin 
intestinal absorption, and serotonin role in gastrointestinal physiology, in this study we 
investigated the association between a common polymorphism in SERT gene and metformin 
gastrointestinal intolerance. 
RESEARCH DESIGN AND METHODS We explored the effect of composite SERT 5-
HTTLPR/rs25531 genotypes, L*L* (LALA), L*S*(LALG, LAS), and S*S* (SS, SLG, LGLG), in 
1,356 fully tolerant and 164 extreme metformin-intolerant patients by using logistic 
regression model, adjusted for age, sex, weight, OCT1 genotype, and concomitant use of 
medications known to inhibit OCT1 activity. 
RESULTS The number of low-expressing SERT S* alleles increased the odds of metformin 
intolerance (OR=1.31, 95% CI 1.02-1.67, P=0.031). Moreover, a multiplicative interaction 
between the OCT1 and SERT genotypes was observed (P=0.003). In the analyses stratified by 
SERT genotype, the presence of two deficient OCT1 alleles was associated with over a nine-
fold higher odds of metformin intolerance in patients carrying L*L* genotype (OR=9.25, 95% 
CI 3.18-27.0, P<10-4), however, it showed much smaller effect in L*S* carriers, and no effect 
in S*S* carriers.  
CONCLUSIONS Our results indicate that interaction between OCT1 and SERT genes might 
play an important role in metformin intolerance. Further studies are needed to replicate these 
findings and to substantiate the hypothesis that metformin gastrointestinal side-effects could 
be related to the reduced intestinal serotonin uptake.  
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Metformin is a first-line antihyperglycaemic agent, and the most widely used type 2 diabetes 
drug. It has major clinical advantages over other therapies due to its proven safety record, it 
does not induce hypoglycaemia or weight gain, and has possible cardiovascular benefits (1). 
The most common adverse effect of metformin treatment is gastrointestinal (GI) upset which 
occurs in approximately 30% of patients, limiting compliance. In 5% of patients treated with 
metformin, GI symptoms are intolerable and warrant the discontinuation of the drug (2). The 
mechanism of metformin GI side effects is not clear. Various pathophysiological hypotheses 
have been proposed, including metformin-induced release of serotonin in the intestinal 
mucosa (3), reduced absorption of bile salts (4), increase in glucagon-like peptide-1 (GLP-1) 
concentrations (5), and more recently, changes in the gut microbiome (6).  
Metformin side effects might be related to high concentration of metformin in the gut after 
oral administration (7). We have recently shown that reduced-function alleles of organic 
cation transporter 1 (OCT1), as well as concomitant treatment with medications known to 
inhibit OCT1 activity, are risk factors for metformin intolerance in a large cohort of type 2 
diabetes patients treated with metformin (8). OCT1 is one of the several cation-selective 
transporters expressed in the enterocytes, which could be involved in metformin absorption 
(9-11). Other potentially involved transporters are OCT3 and plasma membrane monoamine 
transporter (PMAT). Interestingly, a recent study showed that OCT1, PMAT, serotonin 
reuptake transporter (SERT, 5-HTT), and choline high-affinity transporter (CHT), and not 
OCT3, contribute to the apical uptake of metformin into Caco-2 cell monolayers, and thus, 
potentially to intestinal metformin absorption (11). The CHT is not expressed in human 
intestine (11), and there are no established common loss-of-function variants of PMAT. On 
the other hand, the expression of SERT is modulated by genetic variants, most notably the 
serotonin-transporter-linked polymorphic region (5-HTTLPR) variant, a well-established 43-
base pair insertion/deletion polymorphism in the promoter region. Moreover, a recent study 
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showed that metformin can inhibit serotonin uptake by OCT1, OCT3, and SERT, at 
concentrations that may be achieved in human intestine after oral administration (12). These 
findings contribute to the hypothesis of serotonin-mediated GI adverse effects following 
metformin treatment, as metformin inhibition of serotonin uptake could result in increased GI 
side effects (12). 
 
Considering that different expression or activity of SERT might contribute to high inter-
individual variability in GI intolerance to metformin, in this study we investigated the role of 
a common SERT tri-allelic 5-HTTLPR polymorphism in intolerance to metformin, and 
explored the potential interaction between SERT (SLC6A4) and OCT1 (SLC22A1) genes.  
 
RESEARCH DESIGN AND METHODS 
Study population and definition of intolerance  
The study population was previously described in detail (8). Briefly, the study included 
patients with type 2 diabetes from the Genetics of Diabetes Audit and Research Tayside Study 
(GoDARTS), who were prescribed metformin for the first time in the period from 1st January 
1994 to 1st June 2011. A surrogate phenotype of metformin intolerance was defined based on 
discontinuation of metformin within the first 6 months of treatment (immediate release form, 
IR), and switch to another oral hypoglycaemic agent, including metformin slow release forms, 
within 6 months of the last metformin IR prescription. Intolerant patients were compared with 
patients who were defined as tolerant based on treatment with ≥ 2000 mg of metformin IR 
form for more than 6 months.  
 
Clinical cofactors, including anthropometric and biochemical parameters, metformin daily 
dose and use of OCT1-inhibiting medications were defined previously (8). 
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Genotyping  
Genotyping of five OCT1 reduced-function variants (R61C, C88R, G401S, M420del, and 
G465R) and classification of individuals based on the number of haplotypes carrying reduced-
function alleles were described in our previous study (8). 
 
The 5-HTTLPR polymorphism in SERT gene (SLC6A4) is characterised by long (L) and short 
(S) alleles. The S allele has been associated with lower SERT expression and function (13). A 
single nucleotide polymorphism (SNP), rs25531 A>G, located within this region, further 
modulates SERT expression, with LA carriers having higher SERT expression, and LG lower 
SERT expression similar to that in S allele carriers (14). In this study, we predicted the 5-
HTTLPR polymorphism based on published machine learning method of vertex discriminant 
analysis validated for Northern European populations (15). This method uses eight variants in 
partial linkage disequilibrium with 5-HTTLPR, to predict three genotypes, LL, SL and SS 
(15). Seven out of eight SNPs, and rs25531, were imputed from existing genome-wide data on 
7,319 GoDARTS participants using the 1,000 Genome reference panel and software 
IMPUTE2. The imputation quality information values were between 0.88 and 1.00. All SNPs 
were in line with Hardy-Weinberg equilibrium (P > 0.05). Considering that LG allele has the 
same expression as the S allele, the tri-allelic 5-HTTLPR genotypes were coded as L*L* 
(LALA), L*S*(LALG, LAS), and S*S* (SS, SLG, LGLG).      
 
Statistical analysis 
Differences in quantitative variables between two groups were compared using a t test or 
Mann-Whitney U test, depending on the distribution normality, and categorical variables were 
compared using a χ2 test. For testing the significance of the additive genetic model, groups of 
quantitative variables were compared using ANOVA test for trend or Jonckheere's trend test, 
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depending on the distribution normality, and categorical variables were compared using the 
Cochran-Armitage trend test. The logistic regression model was used to analyse the 
association of genotypes with metformin intolerance, with age, sex, weight and the 
concomitant use of OCT1-inhibiting medications as covariates (8). Based on our previous 
study, the effect of two deficient OCT1 alleles was assessed (recessive model) (8), and for the 
tri-allelic 5-HTTLPR polymorphism, an additive genetic model was used. The multiplicative 
interaction was assessed by adding an interaction term to the regression model. Statistical 
analyses were conducted using the SAS 9.3 software (SAS Institute Inc., Cary, NC), and 
statistical significance level was set to P < 0.05. 
 
RESULTS 
A total of 1,356 tolerant and 164 intolerant patients with available OCT1 and SERT genotype 
data were included in the study (Table 1). Patients differed in baseline characteristics, in line 
with our previous study (8). The OCT1 or SERT genotypes were not associated with study 
participants’ baseline characteristics, with the exception of lower percentage of the 
antidiabetic drug-naïve patients in the group with two deficient OCT1 alleles compared to one 
or no deficient OCT1 allele carriers (Supplementary Table 1, P=0.003). 
 
The numbers of individuals in each genotype group are shown in Supplementary Table 2. In 
addition to the association of the two deficient OCT1 alleles with intolerance (recessive 
model, P=0.001) in line with our previous report (8), there was a significant difference in the 
SERT genotype frequencies between the intolerant and tolerant group (additive model, 
P=0.019). 
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In the logistic regression analysis model adjusted for the clinical covariates age, sex and 
weight, the number of S* alleles was associated with higher odds of metformin intolerance 
(OR=1.28, 95% CI 1.01-1.63, P=0.040). This effect was greater after adding the OCT1 
genotype and OCT1-inhibiting medications to the model (Table 2, OR=1.31, 95% CI 1.02-
1.67, P=0.031). Furthermore, we tested the interaction between the OCT1 and SERT 
genotypes. A negative multiplicative interaction was observed between the two genes 
(P=0.003), which is visually presented in Figure 1. This shows the joint effects of OCT1 and 
SERT genotypes compared to the reference genotype group (the combination of one or no 
deficient OCT1 alleles and the L*L* genotype). In the analysis stratified by SERT genotypes, 
the presence of two deficient OCT1 alleles was associated with over a nine-fold higher odds 
of metformin intolerance (OR=9.25, 95% CI 3.18-27.0, P<10-4) in individuals with L*L* 
genotype, whereas there was no significant association in L*S* carriers (OR=2.11, 95% CI 
0.99-4.50, P=0.054) and the S*S* genotype group (OR=0.45, 95% CI 0.09-2.20, P=0.325) 
(Table 3). On the other hand, when patients were stratified according to the OCT1 genotypes, 
the number of S* alleles increased intolerance in carriers of one or no deficient OCT1 allele 
(OR=1.48, 95% CI 1.15-1.92, P=0.003), but showed opposite effect in two deficient OCT1 
allele carriers (OR=0.33, 95% CI 0.13-0.82, P=0.017) (Table 3). 
 
CONCLUSIONS 
In the first study of genetic and phenotypic determinants of metformin intolerance, we 
showed that variants of highly polymorphic OCT1 gene are associated with severe intolerance 
leading to discontinuation of metformin therapy (8). We hypothesised this based on the 
possible role of OCT1 in metformin intestinal absorption. Our later prospective study 
demonstrated the relationship between OCT1 deficient alleles and common GI side effects of 
metformin, thus replicating earlier findings and extending them also to the milder intolerance 
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phenotype (16). The mechanism for this association, however, was unclear. Based on the 
recent findings that metformin may alter serotonin uptake by gut transporters (12), and 
considering the role of serotonin in GI physiology, here we focused on the effect of a common 
and well-established SERT 5-HTTLPR functional polymorphism on metformin intolerance.  
 
We found that the low-expressing S* allele of SERT gene is associated with increased 
intolerance to metformin, although this effect was smaller than that seen to be associated with 
two OCT1 deficient alleles. The 5-HTTLPR polymorphism has been extensively studied 
previously, and there is a possible association of 5-HTTLPR alleles with irritable bowel 
syndrome (17), psychiatric traits (18), and antidepressant drug response (19). Although results 
of the pharmacogenetic studies have been inconsistent, evidence from reviews and meta-
analyses suggest that the L allele is a predictor of better response to selective serotonin 
reuptake inhibitors (SSRIs) in Caucasian populations (19). On the other hand, in the meta-
analysis of nine studies, the S allele was significantly associated with more total adverse 
effects after SSRIs treatment, and showed a trend of association with GI side effects induced 
by SSRIs (20), in line with our results.  
 
In humans, serotonin is predominantly synthesised in the enterochromaffin cells of the gut 
mucosa. Here it mediates many gastrointestinal functions, including motility, secretion and 
vasodilation by activating afferent neurons in the lamina propria (21). Serotonin has been 
involved in the pathophysiology of a number of GI disorders, and drugs targeting serotonin 
receptors have been used in the treatment of GI symptoms (21). Previously it has been shown 
that metformin can induce serotonin release from the intestinal mucosa, in dose-dependent 
manner, without effect on 5-HT3 receptors (3). In this study, the effect of metformin on 
serotonin reuptake was not explored (3). However, recent in vitro findings showed that 
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metformin can inhibit serotonin uptake by SERT and other cation transporters (12). Thus, 
metformin could increase serotonin extracellular concentrations resulting in prolonged 
serotonergic signalling in the intestine and increased GI side effects (12). Although in this 
study, metformin inhibited serotonin uptake by OCT1 more strongly than by SERT (12), 
another in vitro study showed conversely that metformin is not a significant inhibitor of 
OCT1-mediated serotonin transport (22). Beside this, SERT has much higher expression than 
OCT1 in the human intestine (11, 23), implying that although metformin is a weak SERT 
inhibitor, it could inhibit SERT at the high concentrations achieved in the gut after oral 
administration (24). In addition, it has been proposed that inhibition of intestinal SERT may 
contribute to GI adverse effects commonly observed with SSRIs treatment (25), and possibly 
also to side effects of other drugs which may act as SERT inhibitors (26). 
 
As we observed a significant interaction between OCT1 and SERT genotypes, we performed 
analyses stratified by each genotype. Interestingly, in the analyses stratified by SERT 
genotype, two OCT1 deficient alleles had high effect in patients carrying L*L* genotype, 
much smaller effect in L*S* carriers, and no effect in the S*S* genotype carriers. Furthermore, 
the low-expressing S* allele was associated with intolerance only in patients with one or no 
deficient OCT1 allele, and showed opposite direction in carriers of two deficient OCT1 
alleles. It can be hypothesised that low activity of OCT1, possibly the main intestinal 
transporter of metformin, results in increased metformin concentrations in the gut, which can 
inhibit SERT and thus cause high extracellular serotonin levels and GI intolerance. On the 
other hand, although the number of low-expressing SERT S* alleles was associated with 
intolerance per se presumably also due to higher serotonin extracellular levels, the S* allele 
showed protective effect in the presence of two low-activity OCT1 alleles. This contradictory 
finding could be possibly explained by desensitization of serotonin receptors, which may 
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occur as a consequence of greatly increased interstitial serotonin concentrations, in the case of 
low SERT expression (27) and high SERT inhibitor concentrations (28). However, the small 
numbers of patients especially in some of these genotype-stratified analyses preclude drawing 
strong conclusions about the observed interaction. SERT is expressed at both apical and 
basolateral membranes of the enterocytes, with predominant apical expression (11). However, 
there is ambiguity around the localisation of the OCT1 in the enterocytes, as it has been 
suggested to be located basolaterally (9, 29), and conversely, in a recent study, apically (10). 
Thus, it is unclear whether increased mucosal or luminal metformin concentrations could 
contribute to the GI adverse effects. Nevertheless, the results of our study suggest a plausible 
hypothesis for GI intolerance of metformin, which should be explored further.  
 
In addition to the small sizes of groups in the stratified analyses, there are several other 
limitations of our study which need to be acknowledged. Firstly, we used a surrogate 
phenotype for metformin gastrointestinal intolerance based on discontinuation of metformin 
in the first months of treatment. We ensured that patients were switched to another oral 
hypoglycaemic agent, thus the cessation of metformin was not due to improvement in 
glycaemic control. However, there could be other reasons for stopping metformin, including 
other side effects or other reasons not related to drug intolerance. This could result in some 
imprecision in the definition of phenotype categories, although GI intolerance represents the 
most common adverse effect of metformin treatment. Furthermore, it would be interesting to 
explore the effect of concomitant treatment of SSRIs on metformin intolerance, and their 
interaction with SERT as well as OCT1 genotypes. However, we were not able to do this due 
to the small number of patients who were treated with SSRIs. In addition, SSRIs could also 
act as OCT1 inhibitors, and citalopram has been included in the overall OCT1-inhibiting 
drugs. Finally, considering the relatively small size of our study, the novel findings of our 
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study should considered preliminary and require independent replication. Beside this, as 
clearly genetic studies alone cannot infer molecular mechanisms of drug effects, further in 
vitro and in vivo studies are needed to explore the proposed hypothesis of metformin GI 
intolerance. 
 
In conclusion, our results indicate that SERT genotype and the interaction between OCT1 and 
SERT genes might play an important role in GI intolerance to metformin. Further studies are 
needed to replicate our preliminary findings as well to substantiate the proposed interaction 
between metformin and serotonin disposition in the intestine, and elucidate the exact 
mechanisms of GI intolerance to metformin. 
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Table 1. Baseline characteristics of metformin intolerant and tolerant group. 
 Intolerant group (n=164) Tolerant group (n=1356) P 
Age (years) 68.8 ± 9.7 58.4 ± 10.6 <0.001 
Age at diagnosis (years) 63.5 ± 9.9 55.2 ± 10.3 <0.001 
Females/Males (Females %) 94/70 (57.3%) 545/811 (40.2%) <0.001 
Weight (kg) 81.7 ± 15.5 92.1 ± 18.3 <0.001 
BMI (kg/m2) 30.4 ± 5.4 32.6 ± 6.1 <0.001 
HbA1c (%) 
           (mmol/mol) 
8.1 (7.7-9.2) 
65 (61-77) 
8.8 (7.8-9.9) 
73 (62-85) 
<0.001 
Creatinine (µmol/l) 87.4 ± 14.4 87.2 ± 14.4 0.831 
Creatinine clearance (ml/min) 74.4 (57.4-91.4) 97.7 (77.0-120.7) <0.001 
Antidiabetic drug-naive 86 (52.4%) 831 (61.3%) 0.029 
Use of OCT1 inhibiting drugs* 83 (50.6%) 450 (33.2%) <0.001 
Metformin daily dose (mg) 1000 (1000-1000) 1000 (1000-1500) <0.001 
P values refer to the significance of t test, Mann-Whitney U test or a χ2 test for data presented 
as means ± SD, medians (interquartile range), or numbers (percentages), respectively. 
*Number of individuals concomitantly treated with OCT1 inhibiting drugs, including proton 
pump inhibitors, tricyclic antidepressants, citalopram, verapamil, diltiazem, doxazosin, 
spironolactone, clopidogrel, rosiglitazone, quinine, tramadol and codeine. 
 
 
 
 
 
 
 
 
 
16 
 
Table 2. Results of logistic regression model for metformin intolerance. 
 
 OR (95% CI) P 
Age 1.11 (1.08-1.13) <0.001 
Sex (Females vs. Males) 1.82 (1.26-2.65) 0.002 
Weight 0.99 (0.97-1.00) 0.031 
Use of OCT1 inhibiting drugs 1.75 (1.22-2.49) 0.002 
Two reduced-function OCT1 alleles 2.27 (1.31-3.92) 0.003 
Number of SERT S* alleles 1.31 (1.02-1.67) 0.031 
OR, odds ratio for intolerance. Logistic regression analysis included 164  
intolerant and 1356 tolerant patients.  
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Table 3. Stratified analyses according to OCT1 and SERT genotypes. 
Effect of two deficient OCT1 alleles - analysis stratified for SERT genotype 
SERT genotype OR (95% CI) P 
L*L* carriers* 9.25 (3.18-27.0) <0.0001 
L*S* carriers†  2.11 (0.99-4.50) 0.054 
S*S* carriers‡  0.45 (0.09-2.20) 0.325 
Effect of the number of SERT S* alleles - analysis stratified for OCT1 genotype 
OCT1 genotype OR (95% CI) P 
0 or 1 deficient alleles carriers§ 1.48 (1.15-1.92) 0.003 
2 deficient alleles carriers||  0.33 (0.13-0.82) 0.017 
OR, odds ratio for intolerance. Analyses were adjusted for age, sex, weight, and use of  
OCT1-inhibiting medications.* 34 intolerant and 382 tolerant patients; † 81 intolerant and  
656 tolerant patients; ‡ 49 intolerant and 318 tolerant patients; § 141 intolerant and  
1265 tolerant patients; ||23 intolerant and 91 tolerant patients. 
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Figures 
Figure 1 Joint effects of OCT1 and SERT genotypes on metformin intolerance. The 
combination one or no deficient OCT1 alleles/ L*L* is used as a reference group. The 
numbers in each genotype group are presented for the intolerant and tolerant individuals as 
‘Intolerant/Tolerant’. 
 
 
 
 
 
 
 

Supplementary Table 1. Baseline characteristics of study participants according to OCT1 and SERT genotypes. 
 OCT1 genotype  SERT genotype  
 0 or 1 deficient OCT1 
alleles (n=1406) 
2 deficient OCT1 
alleles (n=114) 
 
P 
L*L* genotype 
(n=416) 
L*S* genotype 
(n=737) 
S*S* genotype 
(n=367) 
 
P 
Age (years) 59.5 ± 11.0 60.2 ± 10.5 0.486 59.6 ± 11.0 58.9 ± 10.7 60.7 ± 11.3 0.164 
Age at diagnosis (years) 56.1 ± 10.6 56.4 ± 9.7 0.714 56.0 ± 10.4 55.9 ± 10.4 56.7 ± 11.0 0.374 
Females/Males (Females %) 584/822 (41.5%) 55/59 (48.3%) 0.163 182/234 (43.8%) 317/420 (43.0%) 140/227 (38.2%) 0.121 
Weight (kg) 90.9 ± 18.4 91.2 ± 17.2 0.897 89.5 ± 17.8 91.8 ± 18.3 91.0 ± 18.7 0.238 
BMI (kg/m2) 32.3 ± 6.1 33.2 ± 5.8 0.133 32.0 ± 5.8 32.7 ± 6.1 32.0 ± 6.3 0.955 
HbA1c (%) 
           (mmol/mol) 
8.7 (7.8-9.8) 
72 (62-84) 
8.7 (7.8-9.6) 
72 (62-81) 
0.887 8.7 (7.8-9.7) 
72 (62-83) 
8.8 (7.8-9.9) 
73 (62-85) 
8.6 (7.7-9.6) 
70 (61-81) 
0.543 
Creatinine (µmol/l) 87.4 ± 14.2 85.3 ± 16.3 0.141 86.5 ± 14.3 87.3 ± 14.7 87.8 ± 13.7 0.231 
Creatinine clearance (ml/min) 94.7 (74.8-117.4) 97.7 (73.0-125.5) 0.679 91.7 (73.4-116.2) 96.1 (76.5-118.4) 94.6 (72.8-117.3) 0.806 
Antidiabetic drug-naive 863 (61.4%) 54 (47.4%) 0.003 266 (63.9%) 441 (59.8%) 210 (57.2%) 0.053 
Use of OCT1 inhibiting drugs* 488 (34.7%) 45 (39.5%) 0.305 133 (32.0%) 282 (38.3%) 118 (32.2%) 0.870 
Metformin daily dose (mg) 1000 (1000-1500) 1000 (1000-1500) 0.808 1000 (1000-1425) 1000 (1000-1500) 1000 (1000-1500) 0.088 
In comparison of two OCT1 genotype groups, P values refer to the significance of t test, Mann-Whitney U test or a χ2 test, and in comparison of three SERT genotype groups, 
P values refer to the significance of ANOVA trend test, Jonckheere's trend test and Cochran-Armitage trend test, for data presented as means ± SD, medians (interquartile 
range), or numbers (percentages), respectively. *Number of individuals concomitantly treated with OCT1 inhibiting drugs, including proton pump inhibitors, tricyclic 
antidepressants, citalopram, verapamil, diltiazem, doxazosin, spironolactone, clopidogrel, rosiglitazone, quinine, tramadol and codeine.
Supplementary Table 2. Number of intolerant and tolerant patients according to OCT1 and 
SERT genotypes. 
Intolerant group 
OCT1 genotype SERT genotype 
L*L* L*S* S*S* Total 
0 or 1 deficient alleles 
  
 
26 (15.9%) 68 (41.5%) 47 (28.7%) 141 (86.0%) 
2 deficient alleles 8 (4.9%) 13 (7.9%) 2 (1.2%) 23 (14.0%) 
Total 34 (20.7%) 81 (49.4%) 49 (29.9%) 164 
Tolerant group 
OCT1 genotype SERT genotype 
L*L* L*S* S*S* Total 
0 or 1 deficient alleles 
  
 
362 (26.7%) 605 (44.6%) 298 (22.0%) 1265 (93.3%) 
 2 deficient alleles 20 (1.5%) 51 (3.8%) 20 (1.5%) 91 (6.7%) 
Total 382 (28.2%) 656 (48.4%) 318 (23.5%) 1356 
There was a significant difference between the intolerant and tolerant group in the OCT1 
genotype frequencies (recessive model, P=0.001 for χ2 test) and the SERT genotype 
frequencies (additive model, P=0.019 for Cochran-Armitage trend test).  
 
 
